Filippo Spriano
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Cutaneous lymphoproliferative disorders research, Monoclonal and Polyclonal Antibodies Research, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes(2020)137 cited
- → PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy(2017)117 cited
- → Targeting BET bromodomain proteins in cancer: The example of lymphomas(2020)73 cited
- → Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734(2020)70 cited
- → The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents(2019)69 cited
- → The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models(2019)43 cited
- → Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer(2021)43 cited
- → Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models(2020)41 cited
- → Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma(2017)40 cited
- → Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models(2020)39 cited